Novo Nordisk (NVO) PT Lowered to $105 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman lowered the price target on Novo Nordisk (NYSE: NVO) to $105.00 (from $156.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
